S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20

OptimizeRx Stock Forecast, Price & News

-0.73 (-1.05%)
(As of 11/26/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
119,376 shs
Average Volume
251,228 shs
Market Capitalization
$1.22 billion
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive OPRX News and Ratings via Email

Sign-up to receive the latest news and ratings for OptimizeRx and its competitors with MarketBeat's FREE daily newsletter.

OptimizeRx logo

About OptimizeRx

OptimizeRx Corp. is digital health company, which engages in the provision of digital health messaging via electronic health records, which serves as a direct channel for pharmaceutical companies to communicate with healthcare providers. It offers electronic health record (EHR) workflow solutions which include financial messaging, patient education, and brand messaging; and brand support. The company was founded by David A. Harrell on November 8, 1985 and is headquartered in Rochester, MI.


See More Headlines

Industry, Sector and Symbol

Business services, not elsewhere classified
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$43.31 million
Cash Flow
$0.11 per share
Book Value
$7.14 per share


Net Income
$-2.21 million
Pretax Margin




Free Float
Market Cap
$1.22 billion
Not Optionable

Company Calendar

Last Earnings
Fiscal Year End
Next Earnings (Estimated)


Overall MarketRank

2.45 out of 5 stars

Computer And Technology Sector

174th out of 891 stocks

Business Services, Not Elsewhere Classified Industry

28th out of 136 stocks

Analyst Opinion: 3.5Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 1.9 5 -4 -3 -2 -1 -

OptimizeRx (NASDAQ:OPRX) Frequently Asked Questions

Is OptimizeRx a buy right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for OptimizeRx in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" OptimizeRx stock.
View analyst ratings for OptimizeRx
or view top-rated stocks.

How has OptimizeRx's stock price been impacted by Coronavirus (COVID-19)?

OptimizeRx's stock was trading at $7.51 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, OPRX shares have increased by 812.0% and is now trading at $68.49.
View which stocks have been most impacted by COVID-19

Are investors shorting OptimizeRx?

OptimizeRx saw a increase in short interest in October. As of October 15th, there was short interest totaling 1,720,000 shares, an increase of 35.4% from the September 30th total of 1,270,000 shares. Based on an average daily trading volume, of 316,700 shares, the short-interest ratio is presently 5.4 days. Approximately 11.2% of the company's stock are short sold.
View OptimizeRx's Short Interest

When is OptimizeRx's next earnings date?

OptimizeRx is scheduled to release its next quarterly earnings announcement on Wednesday, February 23rd 2022.
View our earnings forecast for OptimizeRx

How were OptimizeRx's earnings last quarter?

OptimizeRx Co. (NASDAQ:OPRX) announced its earnings results on Tuesday, November, 9th. The company reported $0.09 earnings per share for the quarter, missing the Zacks' consensus estimate of $0.13 by $0.04. OptimizeRx had a trailing twelve-month return on equity of 2.03% and a net margin of 4.16%. During the same quarter in the previous year, the company posted ($0.01) earnings per share.
View OptimizeRx's earnings history

What price target have analysts set for OPRX?

5 analysts have issued 1 year price objectives for OptimizeRx's stock. Their forecasts range from $54.00 to $112.00. On average, they anticipate OptimizeRx's stock price to reach $92.00 in the next year. This suggests a possible upside of 34.3% from the stock's current price.
View analysts' price targets for OptimizeRx
or view top-rated stocks among Wall Street analysts.

Who are OptimizeRx's key executives?

OptimizeRx's management team includes the following people:
  • Will Febbo, Chief Executive Officer & Director
  • Miriam J. Paramore, President & Chief Strategy Officer (LinkedIn Profile)
  • Edward Stelmakh, Chief Operations & Financial Officer
  • Todd Inman, Chief Technology Officer
  • Marion K. Odence-Ford, Chief Compliance Officer & General Counsel

What other stocks do shareholders of OptimizeRx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other OptimizeRx investors own include InterDigital (IDCC), Bank of Hawaii (BOH), NVIDIA (NVDA), STAG Industrial (STAG), Etsy (ETSY), Marvell Technology (MRVL), Trade Desk (TTD), Verizon Communications (VZ), Advanced Micro Devices (AMD) and Amgen (AMGN).

What is OptimizeRx's stock symbol?

OptimizeRx trades on the NASDAQ under the ticker symbol "OPRX."

Who are OptimizeRx's major shareholders?

OptimizeRx's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.29%), Artisan Partners Limited Partnership (4.25%), PEAK6 Investments LLC (0.00%), Millennium Management LLC (3.31%), Handelsbanken Fonder AB (2.90%) and Avenir Corp (2.89%). Company insiders that own OptimizeRx stock include Douglas P Baker, Douglas P Baker, Ellen O'connor Vos, Gregory D Wasson, Miriam J Paramore, Patrick D Spangler, Stephen L Silvestro, Stephen L Silvestro and William J Febbo.
View institutional ownership trends for OptimizeRx

Which major investors are selling OptimizeRx stock?

OPRX stock was sold by a variety of institutional investors in the last quarter, including Avenir Corp, Wasatch Advisors Inc., Handelsbanken Fonder AB, Peregrine Capital Management LLC, Hillsdale Investment Management Inc., Next Century Growth Investors LLC, Two Sigma Advisers LP, and Bullseye Asset Management LLC. Company insiders that have sold OptimizeRx company stock in the last year include Douglas P Baker, Miriam J Paramore, Patrick D Spangler, Stephen L Silvestro, and William J Febbo.
View insider buying and selling activity for OptimizeRx
or view top insider-selling stocks.

Which major investors are buying OptimizeRx stock?

OPRX stock was acquired by a variety of institutional investors in the last quarter, including PEAK6 Investments LLC, Millennium Management LLC, American Century Companies Inc., Granite Investment Partners LLC, CastleArk Alternatives LLC, Credit Suisse AG, Invesco Ltd., and Dimensional Fund Advisors LP. Company insiders that have bought OptimizeRx stock in the last two years include Ellen O'connor Vos, and Gregory D Wasson.
View insider buying and selling activity for OptimizeRx
or or view top insider-buying stocks.

How do I buy shares of OptimizeRx?

Shares of OPRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is OptimizeRx's stock price today?

One share of OPRX stock can currently be purchased for approximately $68.49.

How much money does OptimizeRx make?

OptimizeRx has a market capitalization of $1.22 billion and generates $43.31 million in revenue each year. The company earns $-2.21 million in net income (profit) each year or $0.14 on an earnings per share basis.

How many employees does OptimizeRx have?

OptimizeRx employs 2,018 workers across the globe.

What is OptimizeRx's official website?

The official website for OptimizeRx is www.optimizerx.com.

Where are OptimizeRx's headquarters?

OptimizeRx is headquartered at 400 WATER STREET SUITE 200, ROCHESTER MI, 48307.

How can I contact OptimizeRx?

OptimizeRx's mailing address is 400 WATER STREET SUITE 200, ROCHESTER MI, 48307. The company can be reached via phone at (248) 651-6568, via email at [email protected], or via fax at 248-453-5529.

This page was last updated on 11/28/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.